06990.HK
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 437.80
+0.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.2B | 2.1B | 1.9B | 1.5B | 803.9M |
| Cost of Revenue | 559.8M | 579.1M | 659.4M | 781.3M | 276.8M |
| Gross Profit | 1.6B | 1.5B | 1.3B | 759.2M | 527.1M |
| Operating Expenses | |||||
| R&D Expense | 1.5B | 1.3B | 1.2B | 1.0B | 846.0M |
| SG&A Expense | 912.9M | 284.7M | 129.2M | 66.2M | 22.9M |
| General & Admin Expense | 195.6M | 46.6M | 38.3M | 63.9M | 22.9M |
| Selling & Marketing Expense | 717.4M | 238.1M | 90.9M | 2.3M | — |
| Other Expenses | (877.2M) | 340.6M | 149.7M | 114.7M | 52.2M |
| Total Operating Expenses | 1.6B | 1.9B | 1.5B | 1.2B | 921.0M |
| Cost and Expenses | 2.1B | 2.5B | 2.1B | 2.0B | 1.2B |
| Operating Income (EBIT) | 54.7M | (466.2M) | (211.4M) | (452.6M) | (393.9M) |
| Non-Operating | |||||
| Interest Income | — | 63.5M | 34.2M | 45.2M | 1.4M |
| Interest Expense | — | 6.2M | 3.8M | 84.3M | 148.8M |
| Net Interest Income | 70.1M | 57.4M | 30.4M | (39.1M) | (147.4M) |
| Other Non-Op Income/Expense | (5.5M) | 110.4M | 68.9M | (15.1M) | (173.4M) |
| Non-Operating Income (excl Interest) | 81.8M | (116.6M) | (72.7M) | (69.2M) | 24.6M |
| EBT (Pre-Tax Income) | 49.2M | (355.8M) | (142.5M) | (467.7M) | (567.4M) |
| Income Tax Expense | 202.4M | 26.2M | 124.2M | 106.4M | 48.7M |
| Bottom Line | |||||
| Net Income | 126.9M | (382.0M) | (266.8M) | (574.1M) | (616.1M) |
| Earnings from Cont. Ops | 126.9M | (382.0M) | (266.8M) | (574.1M) | (616.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 126.9M | (382.0M) | (266.8M) | (522.2M) | (548.1M) |
| Per Share | |||||
| Basic EPS | HK$0.55 | (HK$1.66) | (HK$1.20) | (HK$2.84) | (HK$2.54) |
| Diluted EPS | HK$0.55 | (HK$1.66) | (HK$1.20) | (HK$2.84) | (HK$2.54) |
| Revenue Per Share | HK$9.43 | HK$8.93 | HK$8.72 | HK$8.39 | HK$3.72 |
| Shares | |||||
| Basic Shares Outstanding | 233.3M | 230.5M | 221.6M | 183.6M | 215.8M |
| Diluted Shares Outstanding | 233.3M | 230.5M | 221.6M | 183.6M | 215.8M |
| Profitability Metrics | |||||
| EBITDA | 81.9M | (249.2M) | (47.4M) | (308.3M) | (351.2M) |
| D&A | 109.0M | 100.4M | 91.4M | 75.1M | 67.4M |
| EBIT | (27.1M) | (349.6M) | (138.7M) | (383.4M) | (418.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026